Oculis Holding AG (NasdaqGM: OCS)
Health Care · Pharmaceuticals · CH
$8.34
-3.70% today · -60.5% 1Y
Oculis Holding AG (NasdaqGM: OCS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $514.85M and employs 60 people.
Over the last twelve months the share price has lost 60.5%, trading between 8.30 and 34.48.
Tweenvest scores Oculis Holding AG across four factors: quality 45/100, value 40/100, growth 29/100. Its strongest factor is quality.
OCS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $514.85M
- Revenue (TTM)
- $1.45M
- P/E
- —
- EPS
- -1.39
- Dividend yield
- —
- Beta (5Y)
- 0.27
- 52-week high
- $34.48
- 52-week low
- $8.30
- Avg volume (3M)
- —
- Shares outstanding
- 61.73M
- Employees
- 60
- Next earnings
- —
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
- ISIN
- CH1242303498
- Founded
- 2017
- Listed since
- May 18, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Evonile Pharma LimitedBSE: 500672 | $522.37M | Rs2,047.55 | +4.05% |
| Tilray Brands, Inc.NasdaqGS: TLRY | $519.19M | $3.54 | -1.39% |
| Shandong Sinobioway Biomedicine Co., Ltd.SZSE: 002581 | $516.12M | CN¥5.24 | +2.75% |
| Orchid Pharma LimitedNSEI: ORCHPHARMA | $515.65M | Rs983.95 | -0.61% |
| Evolus, Inc.NasdaqGM: EOLS | $510.57M | $7.73 | -0.90% |
| Synmosa Biopharma CorporationTPEX: 4114 | $510.24M | NT$30.15 | +2.73% |
| Shanghai Shen Lian Biomedical CorporationSHSE: 688098 | $510.08M | CN¥8.32 | -1.65% |
| Shaanxi Kanghui Pharmaceutical Co., Ltd.SHSE: 603139 | $507.15M | CN¥34.01 | -0.50% |
Figures last refreshed Oct 11, 2026.